AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Low density lipoprotein receptor adapter protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q5SW96

UPID:

ARH_HUMAN

Alternative names:

Autosomal recessive hypercholesterolemia protein

Alternative UPACC:

Q5SW96; A2BHI5; Q6TQS9; Q8N2Y0; Q9UFI9

Background:

Low density lipoprotein receptor adapter protein 1, also known as the autosomal recessive hypercholesterolemia protein, plays a crucial role in lipid metabolism. It acts as an adapter protein necessary for the efficient endocytosis of the LDL receptor in specific cells, facilitating the internalization of LDL and its receptor from coated pits. This protein's interaction with phosphoinositides is vital for clathrin bud assembly at the cell surface.

Therapeutic significance:

Given its pivotal role in lipid metabolism and the endocytosis of LDL receptors, Low density lipoprotein receptor adapter protein 1 is directly linked to familial hypercholesterolemia, type 4. This association highlights its potential as a target for therapeutic strategies aimed at treating or managing hypercholesterolemia and its complications, such as atherosclerosis and coronary heart disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.